close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:BMNDF)

0.1140 UNCHANGED
Last Price Updated: 10:31 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1140
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1140
Today's Range 0.1140 - 0.1140
52wk Range 0.0158 - 0.1140
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Via ACCESSWIRE
News headline image
Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Via ACCESSWIRE

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
+32.9%
+32.9%
6 Month
+621.5%
+621.5%
1 Year
+14.0%
+14.0%

More News

Read More
News headline image
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
From Biomind Labs Inc.
Via Business Wire
News headline image
Cybin, GH Research Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 26, 2023 ↗
Via Benzinga
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today ↗
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023 ↗
Via Benzinga
News headline image
New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer's ↗
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022 ↗
Via Benzinga
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022 ↗
Via Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022 ↗
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Biomind Labs: Q3 Financials & FDA Approval For New Chemical Entity Targeting Treatment-Resistant Depression ↗
Via Benzinga
News headline image
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 8, 2022 ↗
Via Benzinga
News headline image
Compass Pathways, Allied Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial ↗
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 3, 2022 ↗
Via Benzinga
News headline image
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today ↗
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From October 26, 2022 ↗
Via Benzinga

Frequently Asked Questions

Is BMNDF publicly traded?
Yes, BMNDF is publicly traded.
What exchange does BMNDF trade on?
BMNDF trades on the OTC Traded
What is the ticker symbol for BMNDF?
The ticker symbol for BMNDF is BMNDF on the OTC Traded
What is the current price of BMNDF?
The current price of BMNDF is 0.1140
When was BMNDF last traded?
The last trade of BMNDF was at 01/13/26 10:31 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today